Commentary|Podcasts|November 16, 2026

Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management

Fact checked by: Ashling Wahner

Drs Armstrong and Tawagi review localized prostate cancer diagnosis and management for 2026, reflecting the rapidly changing landscape.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air® partnered with Two Onc Docs to deliver a comprehensive, board-focused review of localized prostate cancer diagnosis and management for 2026, reflecting the rapidly changing landscape of staging, systemic therapy, and perioperative treatment.

The discussion began with disease presentation and risk assessment, noting that most cases are screen detected by elevated prostate-specific antigen levels and that prostate MRI is increasingly performed before biopsy. Drs Armstrong and Tawagi reviewed risk factors, such as older age, family history, Black African ancestry, and BRCA2 variants. They also explained the TNM staging system, Gleason grading, and National Comprehensive Cancer Network risk stratification. They emphasized that node-positive disease is stage IV in prostate cancer. They also highlighted the expanded role of prostate-specific membrane antigen PET imaging, particularly for high-risk and very high–risk disease, as well as the use of genomic classifiers.

Regarding treatment, they described observation for patients with limited life expectancy, active surveillance, radiation, brachytherapy, and prostatectomy for low-risk disease, as well as radiation with 2 to 3 years of androgen deprivation therapy for high-risk disease. They noted that patients with very high–risk disease should also receive 2 years of abiraterone acetate (Zytiga) plus prednisone. They compared LHRH agonists, which require bicalutamide (Casodex) to prevent testosterone flare, with the antagonists degarelix (Firmagon) and relugolix (Orgovyx). Additionally, they reviewed androgen deprivation therapy (ADT)–associated toxicities and bone health management. Drs Armstrong and Tawagi also addressed biochemical recurrence and salvage radiation, and they concluded by highlighting recent data readouts.


Related to this article